Castle Biosciences Inc (CSTL) is a Healthcare · Diagnostics & Research company listed on NASDAQ. Price $35.62 (-3.15%), Market cap $0.58B, 52-week low–high $14.65 ~ $43.04.
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test wh
Financial statements, price targets, institutional (13F) holdings and related news for Castle Biosciences Inc are updated in real time on BlackAll Trade.
Castle Biosciences Inc trades at $35.62 (-3.15%). Real-time quotes and charts are available on BlackAll Trade.
Castle Biosciences Inc has a market cap of about $0.58B.
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal